{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.48","upperLimit":"17.48","value":"11.17"},{"groupId":"OG001","lowerLimit":"7.62","upperLimit":"15.44","value":"11.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"description":"DOR defined as the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nMelflufen: Intravenous infusion\n\nDexamethasone: Oral tablets","id":"OG000","title":"Arm A: Melflufen+Dexamethasone"},{"description":"Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nPomalidomide: Oral capsules\n\nDexamethasone: Oral tablets","id":"OG001","title":"Arm B: Pomalidomide+Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (all patients randomized to either Arm A or Arm B).","reportingStatus":"POSTED","timeFrame":"From first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause, up to the data cutoff date of 03 Feb 2021 (ie, assessed up to approximately 43 months).","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}